Allergan (AGN) Reports In-Line Q2 EPS of $0.63; Guides Q3/FY08; Declares Qtr. Dividend of $0.05/Share

July 30, 2008 9:09 AM EDT

Allergan, Inc. (NYSE: AGN) reports Q2 EPS of $0.63, ex-items, in-line with the analyst estimate of $0.63. Revenues for the quarter were $1.15 billion, versus the consensus of $1.13 billion.

Sees FY08 sales in the range of $4.47-$4.58 billion, versus the consensus of $4.54 billion. Adjusted EPS for the year are expected to be in the range of $2.57-$2.59, versus the consensus of $2.58. Q3 sales are expected to be $1.09-$1.12 billion, versus $1.13 billion and EPS of $0.64-$0.65, versus $0.67.

Declares a quarterly dividend of $0.05 per common share, payable on September 5 to shareholders of record on August 15.

Allergan, Inc., a multi-specialty healthcare company, discovers, develops, and commercializes specialty pharmaceutical, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatological, breast aesthetics, obesity intervention, urological, and other specialty markets worldwide.

Related Categories

Dividends
Earnings
Guidance
Hot List

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?